A real-world analysis of U.S. healthcare claims suggests that blue light cystoscopy (BLC) can increase detection and follow-up activity for non-muscle-invasive bladder cancer without significantly increasing overall healthcare costs. The study, published in JU Open Plus, compared BLC using Hexvix/Cysview with conventional white light cystoscopy and found no statistically significant difference in per-patient monthly costs.

Better diagnostic technology does not always come with a larger healthcare bill. A new real-world study of bladder-cancer care suggests that may be the case for blue light cystoscopy, a technology designed to help physicians identify tumors that can be harder to see under conventional white light.

Photocure ASA, the Norwegian healthcare technology company focused on bladder cancer, announced publication of a retrospective cohort study examining the healthcare resource utilization and costs associated with blue light versus white light cystoscopy in patients with non-muscle-invasive bladder cancer (NMIBC).

Published in JU Open Plus, the research used claims data from the U.S. Optum Research Database covering procedures performed between June 2011 and May 2023.

Researchers analyzed 794 patients who underwent BLC and 4,764 matched patients who underwent white light cystoscopy (WLC). Costs were evaluated on a per-patient-per-month basis and adjusted to 2023 U.S. dollars.

The central finding is less about whether BLC generates more clinical activity—it did—and more about whether that additional activity produces materially higher costs.

It did not, according to the study.

All-cause healthcare costs averaged $2,987.93 per patient per month for the BLC cohort compared with $2,886.16 for WLC. The difference was not statistically significant, with a p-value of 0.65.

Bladder-cancer-specific costs were similarly close: $1,301.10 per patient per month for BLC versus $1,246.60 for WLC, with a p-value of 0.75.

The findings are relevant because BLC patients underwent more bladder-cancer-related ambulatory visits and had higher levels of certain diagnostic activity. Researchers also found a higher prevalence of carcinoma in situ (CIS) detection among BLC patients during the baseline period.

That additional clinical activity might initially suggest that BLC could increase the economic burden on healthcare systems. Instead, the analysis found no significant cost difference after adjustment using an inverse probability of treatment weighting model that accounted for variable patient follow-up.

The distinction matters for healthcare organizations evaluating diagnostic technologies.

BLC uses a photosensitive imaging agent, Hexvix/Cysview, to make certain bladder tumors more visible during cystoscopy. The technology is particularly relevant to NMIBC, where accurate detection of lesions—including carcinoma in situ—can influence subsequent surveillance and treatment decisions.

White light cystoscopy remains the conventional approach, but the potential for enhanced visualization creates a different economic question: if better detection identifies more disease and leads to more follow-up interventions, does the resulting increase in resource utilization outweigh the clinical benefits?

The new study suggests that, in this real-world dataset, increased utilization did not result in statistically higher costs.

That does not mean BLC is cheaper, nor does it establish that the technology improves long-term survival or reduces total lifetime healthcare expenditure. The researchers themselves call for further studies examining its longer-term oncologic and economic impact.

Those limitations are important when interpreting the findings.

The study was retrospective and based on administrative claims rather than a prospective randomized clinical trial. Claims data can identify procedures, diagnoses and healthcare spending, but they provide less clinical detail than prospective research. Differences between patients receiving BLC and WLC can also reflect physician selection and treatment patterns.

Still, real-world economic evidence is becoming increasingly important as healthcare providers balance clinical innovation with cost pressures.

For hospitals and urology practices, diagnostic technologies are evaluated not only on accuracy but also on their downstream effects. A technology that detects more clinically relevant disease could trigger additional procedures, surveillance visits or testing. Those consequences need to be considered alongside the potential value of earlier or more accurate diagnosis.

That makes the study relevant beyond bladder cancer.

Healthcare systems are increasingly asking technology vendors to demonstrate value-based healthcare outcomes, rather than simply showing that a new tool works in a controlled clinical environment. Evidence from routine practice can help payers, providers and health systems understand how a technology behaves once it enters a complex care pathway.

The findings also reinforce the importance of looking beyond the price of a procedure.

A diagnostic technology with a higher upfront cost may still have a different economic profile if it changes treatment decisions, reduces missed disease or affects subsequent utilization. Conversely, additional diagnostic activity does not automatically mean that a technology creates unsustainable costs.

For Photocure, the publication adds economic evidence to the broader clinical case for BLC.

“This real-world results are encouraging,” said Mark Tyson, the study’s principal investigator, arguing that the findings support the clinical utility of BLC and its cost-neutral profile.

The more consequential question is what happens over a longer period.

NMIBC is characterized by a need for ongoing surveillance, making diagnostic accuracy particularly important over repeated cycles of care. Whether improved detection ultimately translates into fewer recurrences, better treatment decisions or lower long-term costs requires evidence extending beyond the study’s observation framework.

For healthcare executives, the immediate takeaway is narrower but still significant: in this analysis, blue light cystoscopy was associated with greater clinical utilization but did not produce a statistically significant increase in monthly healthcare costs.

That could make economic neutrality an important consideration as providers evaluate advanced diagnostic technologies alongside clinical effectiveness, workflow requirements and patient outcomes.

Market Landscape

The bladder-cancer diagnostics market sits at the intersection of medical imaging, urology, pathology and value-based healthcare.

Conventional white light cystoscopy remains a core diagnostic tool for bladder cancer, while enhanced techniques such as blue light cystoscopy seek to improve visualization of lesions that may be difficult to identify under standard illumination.

The economic question is increasingly important as health systems evaluate new technologies through total-care costs rather than procedure-level pricing.

For enterprise healthcare organizations, adoption decisions typically involve several variables: diagnostic performance, capital and procedural costs, physician workflow, training, reimbursement, downstream interventions and patient outcomes.

The Photocure study contributes real-world evidence to that equation, but it does not settle it. Its retrospective design, use of claims data and focus on per-patient monthly costs mean additional prospective and long-term research remains necessary.

The broader direction of healthcare technology is toward technologies that can demonstrate both clinical utility and measurable economic value. Similar pressures are shaping adoption decisions across medical imaging, AI-assisted diagnostics, remote monitoring and precision medicine.

Top Insights

• Photocure’s claims analysis found no significant cost difference between blue and white light cystoscopy despite greater ambulatory utilization among BLC patients.
• The study analyzed 794 BLC patients and 4,764 matched WLC patients using U.S. Optum claims data spanning 2011 through 2023.
• Blue light cystoscopy was associated with greater detection of carcinoma in situ, highlighting potential clinical value alongside increased surveillance activity.
• For health systems, the findings strengthen the case for evaluating diagnostic technologies through total healthcare utilization rather than procedure costs alone.
• Long-term research remains necessary to determine whether improved detection produces measurable differences in recurrence, outcomes and lifetime healthcare spending.

Join thousands of HR leaders who rely on HRTechEdge for the latest in workforce technology, AI-driven HR solutions, and strategic insights